As of 21 March 2020, the CDC recommends RT-PCR for initial screening. The presence of viruses is generally confirmed by RT-PCR, which detects the coronavirus' RNA. This test detects only the RNA of the SARS-CoV-2 and is used to confirm very recent or active infections.
Detection of antibodies (serology) can be used both for diagnosis and population surveillance. Antibody tests show how many people have had the disease, including those whose symptoms were minor or who were asymptomatic. An accurate mortality rate of the disease and the level of herd immunity in the population can be determined from the results of this test.
Due to limited testing, as of March 2020 no countries had reliable data on the prevalence of the virus in their population. By 23 March, no country had tested more than 3% of their population, and there are variations in how much testing has been done across countries. This variability is also likely to be affecting reported case fatality rates, which have probably been overestimated in many countries, due to sampling bias.
|China||China CDC||ORF1ab and nucleoprotein (N)|
|Germany||Charité||RdRP, E, N|
|Hong Kong||HKU||ORF1b-nsp14, N|
|Japan||NIID||Pancorona and multiple targets,|
Spike protein (Peplomer)
|Thailand||National Institute of Health||N|
|United States||US CDC||Three targets in N gene|
|France||Pasteur Institute||Two targets in RdRP|
Test methods[edit source | edit]
RT-PCR[edit source | edit]
Using real-time reverse transcription polymerase chain reaction (rRT-PCR) the test can be done on respiratory samples obtained by various methods, including a nasopharyngeal swab or sputum sample. Results are generally available within a few hours to 2 days. The RT-PCR test performed with throat swabs is only reliable in the first week of the disease. Later on the virus can disappear in the throat while it continues to multiply in the lungs. For infected people tested in the second week, alternatively sample material can then be taken from the deep airways by suction catheter or coughing up material (sputum) can be used.
Demonstration of a nasopharyngeal swab for COVID-19 testing
Demonstration of a throat swab for COVID-19 testing
INAA[edit source | edit]
On 27 March 2020, the FDA approved an "automated assay" from Abbott Diagnostics Scarborough "that utilizes isothermal nucleic acid amplification technology". On 13 April, Health Canada approved a similar test from Spartan Bioscience. The benefit of these isothermal tests is that institutions may "test patients" with a handheld DNA analyzer "and receive results without having to send samples away to a [central] lab."
Serology tests[edit source | edit]
Most serology tests are in the research stage of development. As of 10 April, only a single test had been approved for diagnosis in the United States and this is under FDA Emergency Use Authorization (EUA). This test, when tested in China, had a specificity of 95.6% and a sensitivity of 93.8%. A highly sensitive test rarely overlooks an actual positive. A highly specific test rarely registers a positive classification for anything that is not the target of testing. Other tests have been approved in other countries.
Part of the immune response to infection is the production of antibodies including IgM and IgG. According to the FDA, IgM antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although levels over the course of infection are not well characterized. IgG antibodies to SARS-CoV-2 become detectable later following infection. Antibody tests can be used to determine the percentage of the population that has contracted the disease and that is therefore immune.
Assays can be performed in central laboratories (CLT) or by point-of-care testing (PoCT). The high-throughput automated systems in many clinical laboratories will be able to perform these assays but their availability will depend on the rate of production for each system. For CLT a single specimen of peripheral blood is commonly used, although serial specimens can be used to follow the immune response. For PoCT a single specimen of blood is usually obtained by skin puncture. Unlike PCR methods an extraction step is not needed before assay.
In late March 2020, a number of companies received European approvals for their test kits. The testing capacity is several hundred samples within hours. The antibodies are usually detectable 14 days after the onset of the infection.
In early April, the UK found none of the antibody test kits it purchased were sufficiently good to use.
Medical imaging[edit source | edit]
Chest CT scans may be helpful to diagnose COVID-19 in individuals with a high clinical suspicion of infection based on risk factors and symptoms but is not recommended for routine screening. Typical features on CT initially include bilateral multilobar ground-glass opacities with a peripheral, asymmetric and posterior distribution. Subpleural dominance, crazy paving, and consolidation may develop as the disease evolves.
Approaches to testing[edit source | edit]
Hong Kong has set up a scheme where suspected patients can stay home, "[the] emergency department will give a specimen tube to the patient", they spit into it, send it back and get a test result a while after.
Several countries are aiming to conduct 100,000 tests per day – Germany by mid-April, the United Kingdom by the end of April and France by the end of June. Germany has a large medical diagnostics industry, with over 100 testing labs that provided the technology and infrastructure to enable rapid increases in testing. The UK sought to diversify its life sciences companies into diagnostics to scale up testing capacity.
By the start of April, the United Kingdom was delivering around 10,000 swab tests per day. It set a target for 100,000 per day by the end of April, eventually rising to 250,000 tests per day. The British NHS has announced that it is piloting a scheme to test suspected cases at home, which removes the risk of a patient infecting others if they come to a hospital or having to disinfect an ambulance if one is used.
In drive-through testing for COVID-19 for suspected cases, a healthcare professional takes sample using appropriate precautions. Drive-through centers have helped South Korea do some of the fastest, most-extensive testing of any country.
In Germany, the National Association of Statutory Health Insurance Physicians said on 2 March, that it had a capacity for about 12,000 tests per day in the ambulatory setting and 10,700 had been tested in the prior week. Costs are borne by the health insurance when the test is ordered by a physician. According to the president of the Robert Koch Institute, Germany has an overall capacity for 160,000 tests per week. As of 19 March drive in tests were offered in several large cities. As of 26 March, the total number of tests performed in Germany was unknown, because only positive results are reported. Health minister Jens Spahn estimated 200,000 tests/week. A first lab survey revealed that as of the end of March a total of at least 483,295 samples were tested and 33,491 samples (6.9%) tested positive for SARS-CoV-2.
In Israel, researchers at Technion and Rambam Hospital developed and tested a method for testing samples from 64 patients simultaneously, by pooling the samples and only testing further if the combined sample is found to be positive.
In Wuhan a makeshift 2000-sq-meter emergency detection laboratory named "Huo-Yan" (Chinese: 火眼, "Fire Eye") was opened on 5 February 2020 by BGI, which can process over 10,000 samples a day. With the construction overseen by BGI-founder Wang Jian and taking 5-days, modelling has show cases in Hubei would have been 47% higher and the corresponding cost of the tackling the quarantine would have doubled if this testing capacity had not come into operation. The Wuhan Laboratory has been promptly followed by Huo-Yan labs in Shenzhen, Tianjin, Beijing, and Shanghai, in a total of 12 cities across China. By 4 March 2020 the daily throughput totals were 50,000 tests per day.
Open source, multiplexed designs released by Origami Assays have been released that can test as many as 1122 patient samples for COVID19 using only 93 assays. These balanced designs can be run in small laboratories without the need for robotic liquid handlers.
By March, shortages and insufficient amounts of reagent has become a bottleneck for mass testing in the EU and UK and the US. This has led some authors to explore sample preparation protocols that involve heating samples at 98 °C (208 °F) for 5 minutes to release RNA genomes for further testing.
On 31 March it was announced United Arab Emirates was now testing more of its population for Coronavirus per head than any other country, and was on track to scale up the level of testing to reach the bulk of the population. This was through a combination of drive-through capability, and purchasing a population-scale mass-throughput laboratory from Group 42 and BGI (based on their "Huo-Yan" emergency detection laboratories in China). Constructed in 14 days, the lab is capable of conducting tens of thousands RT-PCR tests per day and is the first in the world of this scale to be operational outside of China.
Production and volume[edit source | edit]
Different testing recipes targeting different parts of the coronavirus genetic profile were developed in China, France, Germany, Hong Kong, Japan, the United Kingdom, and the United States. The World Health Organization adopted the German recipe for manufacturing kits sent to low-income countries without the resources to develop their own. The German recipe was published on 17 January 2020; the protocol developed by the United States Centers for Disease Control (CDC) was not available until 28 January, delaying available tests in the U.S.
China and the United States had problems with the reliability of test kits early in the outbreak, and these countries and Australia were unable to supply enough kits to satisfy demand and recommendations for testing by health experts. In contrast, experts say South Korea's broad availability of testing helped reduce the spread of the novel coronavirus. Testing capacity, largely in private sector labs, was built up over several years by the South Korean government. On 16 March, the World Health Organization called for ramping up the testing programmes as the best way to slow the advance of COVID-19 pandemic.
High demand for testing due to wide spread of the virus caused backlogs of hundreds of thousands of tests at private U.S. labs, and supplies of swabs and chemical reagents became strained.
Available tests[edit source | edit]
PCR based[edit source | edit]
Public Health England developed a test by 10 January, using real-time RT-PCR (RdRp gene) assay based on oral swabs. The test detected the presence of any type of coronavirus including specifically identifying SARS-CoV-2. It was rolled out to twelve laboratories across the United Kingdom on February 10. Another early PCR test was developed at Charité in Berlin in January 2020 using rtRT-PCR, and formed the basis of 250,000 kits for distribution by the World Health Organization (WHO).
The South Korean company Kogenebiotech developed a clinical grade, PCR-based SARS-CoV-2 detection kit (PowerChek Coronavirus) on 28 January 2020. It looks for the "E" gene shared by all beta coronaviruses, and the RdRp gene specific to SARS-CoV-2.
In the United States, the CDC distributed its SARS-CoV-2 Real Time PCR Diagnostic Panel to public health labs through the International Reagent Resource. One of three genetic tests in older versions of the test kits caused inconclusive results due to faulty reagents, and a bottleneck of testing at the CDC in Atlanta; this resulted in an average of fewer than 100 samples a day being successfully processed throughout the whole of February 2020. Tests using two components were not determined to be reliable until 28 February 2020, and it was not until then that state and local laboratories were permitted to begin testing. The test was approved by the FDA under an EUA.
US commercial labs began testing in early March 2020. As of 5 March 2020 LabCorp announced nationwide availability of COVID-19 testing based on RT-PCR. Quest Diagnostics similarly made nationwide COVID-19 testing available as of 9 March 2020.
In Russia, the COVID-19 test was developed and produced by the State Research Center of Virology and Biotechnology VECTOR. On 11 February 2020 the test was registered by the Federal Service for Surveillance in Healthcare.
On 19 March 2020, the FDA issued EUA to Abbott Laboratories for a test on Abbott's m2000 system; the FDA had previously issued similar authorization to Hologic, LabCorp, and Thermo Fisher Scientific. On 21 March 2020, Cepheid similarly received an EUA from the FDA for a test that takes about 45 minutes on its GeneXpert system; the same system that runs the GeneXpert MTB/RIF.
Isothermal nucleic amplification[edit source | edit]
The FDA has approved a test by Abbott Laboratories that uses isothermal nucleic acid amplification technology instead of PCR. Since this does not require a series of alternating temperature cycles this method can deliver positive results in as little as five minutes and negative results in 13 minutes. There are currently about 18,000 of these machines in the U.S. and Abbott expects to ramp up manufacturing to deliver 50,000 tests per day.
Accuracy[edit source | edit]
In March 2020 China reported problems with accuracy in their test kits.
In the United States, the test kits developed by the CDC had "flaws;" the government then removed the bureaucratic barriers that had prevented private testing.
Spain purchased test kits from Chinese firm Shenzhen Bioeasy Biotechnology Co Ltd, but found that results were inaccurate. The firm explained that the incorrect results may be a result of a failure to collect samples or use the kits correctly. The Spanish ministry said it will withdraw the kits that returned incorrect results, and would replace them with a different testing kit provided by Shenzhen Bioeasy.
Confirmatory testing[edit source | edit]
WHO recommends that countries that do not have testing capacity and national laboratories with limited experience on COVID-19 send their first five positives and the first ten negative COVID-19 samples to one of the 16 WHO reference laboratories for confirmatory testing. Out of the 16 reference laboratories, 7 are in Asia, 5 in Europe, 2 in Africa, 1 in North America and 1 in Australia.
WHO Emergency Use Listing[edit source | edit]
|Date listed||Product name||Manufacturer|
|03/4/2020||Cobas SARS-CoV-2 qualitative assay for use on the cobas 6800/8800 Systems||Roche Molecular Systems|
|07/4/2020||Coronavirus (COVID-19) genesig rtPCR assay||Primerdesign|
As of 7 April 2020, the WHO had accepted two diagnostic tests for procurement under the Emergency Use Listing procedure (EUL) for use during the COVID-19 pandemic, in order to increase access to quality-assured, accurate tests for the disease. Both in vitro diagnostics, the tests are genesig Real-Time PCR Coronavirus (COVID-19) manufactured by Primerdesign, and cobas SARS-CoV-2 Qualitative assay for use on the cobas® 6800/8800 Systems by Roche Molecular Systems. Approval means that these tests can also be supplied by the United Nations and other procurement agencies supporting the COVID-19 response.
Effectiveness[edit source | edit]
Testing, followed with quarantine of those who tested positive and tracing of those with whom the SARS-CoV-2 positive people had had contact, resulted in positive outcomes[clarification needed].
Italy[edit source | edit]
Researchers working in the Italian town of Vò, the site of the first COVID-19 death in Italy, conducted two rounds of testing on the entire population of about 3,400 people, about ten days apart. About half the people testing positive had no symptoms, and all discovered cases were quarantined. With travel to the commune restricted, this eliminated new infections completely.
Singapore[edit source | edit]
With aggressive contact tracing, inbound travel restrictions, testing, and quarantining, the 2020 coronavirus pandemic in Singapore has proceeded much more slowly than in other developed countries, but without extreme restrictions like forced closure of restaurants and retail establishments. Many events have been cancelled, and Singapore did start advising residents to stay at home on 28 March, but schools reopened on time after holiday break on 23 March.
Others[edit source | edit]
Several other countries, such as Iceland and South Korea, have also managed the pandemic with aggressive contact tracing, inbound travel restrictions, testing, and quarantining, but with less aggressive lock-downs. A statistical study has found that countries that have tested more, relative to the number of deaths, have much lower case fatality rates, probably because these countries are better able to detect those with only mild or no symptoms.
Virus testing by country[edit source | edit]
The column “Positive / million people” is influenced by the country's testing policy. A country that only tests people admitted to hospitals will have a higher positive / million people than a country that tests all citizens whether or not they are showing symptoms, assuming the populations of the two countries have the same infection rate. Template:COVID19Testing
Research and development[edit source | edit]
A test which uses monoclonal antibodies which bind to the nucleocapsid protein (N protein) of the SARS-CoV-2 is being developed in Taiwan, with the hope that it can provide results in 15 to 20 minutes just like a rapid influenza test. The World Health Organization raised concerns on April 8 that these tests need to be validated for the disease and are in a research stage only.
References[edit source | edit]
- "Coronavirus Disease 2019 (COVID-19)". Centers for Disease Control and Prevention. 21 March 2020. Retrieved 28 March 2020.
- Ioannidis, John P.A. (17 March 2020). "A fiasco in the making? As the coronavirus pandemic takes hold, we are making decisions without reliable data". STAT. Retrieved 22 March 2020.
- "COVID-19: First results of the voluntary screening in Iceland". Nordic Life Science – the leading Nordic life science news service. 27 March 2020. Retrieved 7 April 2020.
- Ward, D. (April 2020) "Sampling Bias: Explaining Wide Variations in COVID-19 Case Fatality Rates". WardEnvironment.
- Henriques, Martha. "Coronavirus: Why death and mortality rates differ". bbc.com. Retrieved 8 April 2020.
- Michaels, Jonathan A.; Stevenson, Matt D. (2020). "Explaining national differences in the mortality of Covid-19: Individual patient simulation model to investigate the effects of testing policy and other factors on apparent mortality" (PDF). doi:10.1101/2020.04.02.20050633.
- "Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans". who.int. Retrieved 6 March 2020.
- "2019 Novel Coronavirus (2019-nCoV) Situation Summary". Centers for Disease Control and Prevention. 30 January 2020. Archived from the original on 26 January 2020. Retrieved 30 January 2020.
- "Real-Time RT-PCR Panel for Detection 2019-nCoV". Centers for Disease Control and Prevention. 29 January 2020. Archived from the original on 30 January 2020. Retrieved 1 February 2020.
- "Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe". GlobeNewswire News Room. 30 January 2020. Archived from the original on 31 January 2020. Retrieved 1 February 2020.
- Drosten, Christian (26 March 2020). "Coronavirus-Update Folge 22" (PDF). NDR. Archived (PDF) from the original on 31 March 2020. Retrieved 2 April 2020.
- "Letter from FDA". FDA. 27 March 2020. Retrieved 2 April 2020.
- "Health Canada approves new rapid COVID-testing kits". The Globe and Mail Inc. 13 April 2020.
- "Serology-based tests for COVID-19". Johns Hopkins. Retrieved 10 April 2020.
- "Coronavirus (COVID-19) Update: Serological Tests". U.S. Food and Drug Administration. 7 April 2020. Retrieved 9 April 2020.
- "NIH Begins Study to Quantify Undetected Cases of Coronavirus Infection | NIH: National Institute of Allergy and Infectious Diseases". niaid.nih.gov. Retrieved 11 April 2020.
- Mandavilli, Apoorva; Thomas, Katie (10 April 2020). "Will an Antibody Test Allow Us to Go Back to School or Work?". The New York Times. Retrieved 11 April 2020.
- "FDA Emergency Use Authorization". FDA. 1 April 2020. Retrieved 10 April 2020.
- Fellmann F. (March 2020). (in German) "Jetzt beginnt die Suche nach den Genesenen". Tages Anzeiger. Retrieved 28 March 2020.
- Chris Smyth; Dominic Kennedy; Billy Kenber (6 April 2020). "Britain has millions of coronavirus antibody tests, but they don't work". The Times. Retrieved 6 April 2020.
None of the antibody tests ordered by the government is good enough to use, the new testing chief has admitted. Professor John Newton said that tests ordered from China
- "ACR Recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection". American College of Radiology. 22 March 2020.
- Salehi, Sana; Abedi, Aidin; Balakrishnan, Sudheer; Gholamrezanezhad, Ali (14 March 2020). "Coronavirus Disease 2019 (COVID-19): A Systematic Review of Imaging Findings in 919 Patients". American Journal of Roentgenology: 1–7. doi:10.2214/AJR.20.23034. ISSN 0361-803X. PMID 32174129.
- Lee, Elaine Y. P.; Ng, Ming-Yen; Khong, Pek-Lan (24 February 2020). "COVID-19 pneumonia: what has CT taught us?". The Lancet Infectious Diseases. 0 (4): 384–385. doi:10.1016/S1473-3099(20)30134-1. ISSN 1473-3099. PMC 7128449. PMID 32105641. Retrieved 13 March 2020.
- "In Age of COVID-19, Hong Kong Innovates To Test And Quarantine Thousands". NPR.org.
- "Coronavirus (COVID-19): Scaling up our testing programmes" (PDF). Department of Health and Social Care. 4 April 2020.
- "NHS pilots home testing for coronavirus". MobiHealthNews. 24 February 2020. Archived from the original on 25 February 2020.
- email@example.com, Jeff Kiger. "Mayo Clinic starts drive-thru testing for COVID-19". PostBulletin.com. Retrieved 13 March 2020.
- Hawkins, Andrew J. (11 March 2020). "Some states are offering drive-thru coronavirus testing". The Verge. Retrieved 13 March 2020.
- "South Korea's Drive-Through Testing For Coronavirus Is Fast – And Free". npr. 11 March 2020. Retrieved 16 March 2020.
- Nina Weber; Katherine Rydlink; Irene Berres (5 March 2020). "Coronavirus und Covid-19: So testet Deutschland". Der Spiegel (in German). Retrieved 23 March 2020.
- Oltermann, Philip (22 March 2020). "Germany's low coronavirus mortality rate intrigues experts". The Guardian. ISSN 0261-3077. Retrieved 24 March 2020.
- "Covid-19 – Tests auf das Coronavirus: Wann, wo und wie?". Deutschlandfunk (in German). 19 March 2020. Retrieved 24 March 2020.
- Charisius, Hanno (26 March 2020). "Covid-19: Wie gut testet Deutschland?" (in German). Retrieved 26 March 2020.
- Cite error: The named reference
rki26was invoked but never defined (see the help page).
- "Pooling method allows dozens of COVID-19 tests to run simultaneously". medicalxpress.com. Retrieved 24 March 2020.
- "Israeli team has coronavirus test kit to test dozens of people at once". The Jerusalem Post | JPost.com. Retrieved 24 March 2020.
- Staff, Israel21c (19 March 2020). "Israelis introduce method for accelerated COVID-19 testing". Israel21c. Retrieved 24 March 2020.
- "Wuhan Test Lab Opens; CDC Ships Diagnostic Kits: Virus Update". Bloomberg. 5 February 2020. Retrieved 7 February 2020.
- "China virus crisis deepens as whistleblower doctor dies". AFP.com. 27 February 2012. Retrieved 7 February 2020.
- "BGI's Coronavirus Response? Build a Lab in Wuhan". GEN – Genetic Engineering and Biotechnology News. 12 February 2020. Retrieved 27 March 2020.
- "COVID-19 Local Laboratory Solution". BGI – Global. Retrieved 27 March 2020.
- "Origami Assays". Origami Assays. 2 April 2020. Retrieved 7 April 2020.
- "Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK –seventh update" (PDF). European Centre for Disease Prevention and Control. 25 March 2020. pp. 15–16. Retrieved 29 March 2020.
the current shortages of laboratory consumables and reagents affect diagnostic capacity and hamper the epidemic response at the national and local levels. The laboratories have experienced delayed or missing deliveries of swabbing material, plastic consumables, RNA extraction and RT-PCR reagents, and PPE. This is affecting laboratories in all EU/EEA countries.
- Baird, Robert P. (24 March 2020). "Why Widespread Coronavirus Testing Isn't Coming Anytime Soon". The New Yorker. Archived from the original on 28 March 2020. Retrieved 29 March 2020.
South Dakota, said that her state’s public-health laboratory—the only lab doing COVID-19 testing in the state—had so much trouble securing reagents that it was forced to temporarily stop testing altogether. also noted critical shortages of extraction kits, reagents, and test kits
- Ossola, Alexandra (25 March 2020). "Here are the coronavirus testing materials that are in short supply in the US". Quartz. Archived from the original on 26 March 2020. Retrieved 29 March 2020.
extract the virus’s genetic material—in this case, RNA—using a set of chemicals that usually come in pre-assembled kits. “The big shortage is extraction kits” There are no easy replacements here: “These reagents that are used in extraction are fairly complex chemicals. They have to be very pure, and they have to be in pure solution”
- Fomsgaard, Anders (27 March 2020). "Statens Serum Institut (SSI) solves essential COVID-19 testing deficiency problem". en.ssi.dk. Statens Serum Institut. Archived from the original on 29 March 2020.
several countries are in lack of the chemical reagents necessary to test their citizens for the disease.
- "Danish researchers behind simple coronavirus test method". cphpost.dk. The Copenhagen Post. 28 March 2020. Archived from the original on 28 March 2020.
- Sullivan (now, Helen; Rawlinson, earlier); Kevin; Gayle, Damien; Topping, Alexandra; Mohdin, and Aamna; Willsher, Kim; Wintour, Patrick; Wearden, Graeme; Greenfield, Patrick (31 March 2020). "Global confirmed virus death toll passes 40,000 – as it happened". The Guardian. ISSN 0261-3077. Retrieved 1 April 2020.
- "VIDEO: UAE sets up COVID-19 detection lab in just 14 days". Gulf Today. 31 March 2020.
- America’s COVID-19 testing has stalled, and that's a big problem
- "PolitiFact – Biden falsely says Trump administration rejected WHO coronavirus test kits (that were never offered)". @politifact.
- Heartbreak in the Streets of Wuhan
- "State figures on testing raise questions about efforts to contain outbreak". The BostonGlobe.com.
flaws with the testing kits first distributed by the federal government and bureaucratic hurdles that held up testing by private labs at hospitals, universities and testing chains
- Davey, Melissa (14 March 2020). "Australian stocks of coronavirus testing kits 'rapidly deteriorating', says chief medical officer" – via www.theguardian.com.
- "Experts Credit South Korea's Extensive Testing For Curbing Coronavirus Spread". NPR.org.
- "'Test, Test, Test': WHO Chief's Coronavirus Message to World". The New York Times. 16 March 2020. Retrieved 16 March 2020.
- Reuters, Source (16 March 2020). "'Test, test, test': WHO calls for more coronavirus testing – video". The Guardian. Retrieved 16 March 2020.
- Coronavirus Testing Backlogs Continue As Laboratories Struggle To Keep Up With Demand
- "UK defends coronavirus response after Reuters investigation". Reuters. 9 April 2020. Retrieved 12 April 2020.
After developing a test for the new virus by Jan. 10
- "COVID-19 virus testing in NHS laboratories" (PDF). NHS England and NHS Improvement. 16 March 2020.
- "PHE novel coronavirus diagnostic test rolled out across UK". GOV.UK. Retrieved 30 March 2020; "'Increased likelihood' of China virus reaching UK". BBC News. 23 January 2020. Retrieved 30 March 2020; "PHE tells patients with suspected coronavirus to call GP or NHS 111". The Pharmaceutical Journal. 27 January 2020. Retrieved 30 March 2020.
- Sheridan, Cormac (19 February 2020). "Coronavirus and the race to distribute reliable diagnostics". Nature Biotechnology. 38 (4): 382–384. doi:10.1038/d41587-020-00002-2. PMID 32265548.
- "KogeneBiotech". Kogene.co.kr. Retrieved 16 March 2020.
- Jeong, Sei-im (28 February 2020). "Korea approves 2 more COVID-19 detection kits for urgent use – Korea Biomedical Review". koreabiomed.com (in Korean). Retrieved 12 March 2020.
- "ABOUT US | NEWS". kogene.co.kr.
- "BGI Sequencer, Coronavirus Molecular Assays Granted Emergency Use Approval in China". GenomeWeb. Retrieved 9 March 2020.
- "International Reagent Resource". internationalreagentresource.org.
- Transcript for the CDC Telebriefing Update on COVID-19, 28 February 2020
- "LabCorp Launches Test for Coronavirus Disease 2019 (COVID-19)". Laboratory Corporation of America Holdings.
- "Covid19 : COVID-19". questdiagnostics.com.
- "В России зарегистрирована отечественная тест-система для определения коронавируса". Interfax-Russia.ru. 14 February 2020.
- Plumbo, Ginger. "Mayo Clinic develops test to detect COVID-19 infection". Mayo Clinic. Retrieved 13 March 2020.
- "M2000 Realtime System". Abbott Labs. Retrieved 13 April 2020.
- "Hologic's Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization". Hologic. 16 March 2020. Retrieved 13 April 2020.
- "LabCorp Launches Test for Coronavirus Disease 2019 (COVID-19)". LabCorp. Retrieved 13 April 2020.
- "TaqPath COVID-19 Multiplex Diagnostic Solution". ThermoFisher. Retrieved 13 April 2020.
- "FDA Approves Abbott Laboratories Coronavirus Test, Company To Ship 150,000 Kits". IBTimes.com. 19 March 2020. Archived from the original on 20 March 2020.
- "Sunnyvale company wins FDA approval for first rapid coronavirus test with 45-minute detection time". EastBayTimes.com. 21 March 2020. Archived from the original on 22 March 2020.
- "Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use Authorization". www.cepheid.com. Retrieved 13 April 2020.
- "Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as Five Minutes". Abbott. 27 March 2020. Retrieved 2 April 2020.
- 80% of Rapid COVID-19 Tests the Czech Republic Bought From China are Wrong
- VOJTĚCH BLAŽEK (23 March 2020). "Úřad dopředu psal, kdy mohou rychlotesty selhat. I tak je stát nasadil". Zeznam Zprávy (in Czech). Retrieved 7 April 2020.
Indeed, the rapid tests that arrived from China a few days ago do not really reliably detect the infection at an early stage
- Coronavirus test kits purchased from China are unreliable, says Science Committee member – Duvar English
- Coronavirus: Turkey rejects Chinese testing kits over inaccurate results | Middle East Eye
- Coronavirus: Government’s testing chief admits none of 3.5m antibody kits work sufficiently | The Independent
- "National laboratories". who.int.
- "PHE novel coronavirus diagnostic test rolled out across UK". GOV.UK. Retrieved 12 April 2020.
In addition to processing samples from suspected cases in this country, PHE is now working as a reference laboratory for WHO, testing samples from countries that do not have assured testing capabilities.
- "Specimen referral for COVID-19 – operational details of WHO reference laboratories providing confirmatory testing for COVID-19" (PDF). World Health Organization. Retrieved 29 March 2020.
- "WHO lists two COVID-19 tests for emergency use". World Health Organization. Retrieved 10 April 2020.
- "How an experiment helped one Italian town find 'submerged infections,' cut new COVID-19 cases to zero | National Post". 19 March 2020.
- "COVID-19 outbreak: Petition to close schools in Singapore garners 7,700 signatures to date". msn.com.
- "COVID-19: First results of the voluntary screening in Iceland". Nordic Life Science – the leading Nordic life science news service. 27 March 2020. Retrieved 5 April 2020.
- NormileMar. 17, Dennis; 2020; Am, 8:00 (17 March 2020). "Coronavirus cases have dropped sharply in South Korea. What's the secret to its success?". Science | AAAS. Retrieved 5 April 2020.CS1 maint: numeric names: authors list (link)
- "中央研究院網站". sinica.edu.tw. Sinca. Retrieved 12 March 2020.
- "Advice on the use of point-of-care immunodiagnostic tests for COVID-19". who.int. Retrieved 11 April 2020.